Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04814108 · ClinicalTrials.gov registry record · Phase 2

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

A Phase 2 study of Uterine Serous Carcinoma, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
92
Enrollment target
20
Study locations

NCT04814108: Completed Phase 2 study of Uterine Serous Carcinoma, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.

NCT04814108 is a Phase 2 study of Uterine Serous Carcinoma that has completed, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 92 participants, roughly in line with the 89-participant average among 4 other Uterine Serous Carcinoma trials with a reported enrollment target. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04814108, a Phase 2 study of Uterine Serous Carcinoma, has completed, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
92 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

Primary Outcome

To determine the safety and tolerability of ZN-c3 in subjects with recurrent or persistent USC.

Conditions Studied

Uterine Serous Carcinoma

Interventions

  • DRUG Azenosertib

Study Locations (20)

Arizona

  • Honor Health - Phoenix
  • Arizona Oncology Associates Wilmot HOPE - Tucson
  • Banner University Medical Center Tucson - Tucson

Florida

  • Mount Sinai Medical Center - Miami Beach
  • Sarasota Memorial Hospital - Sarasota
  • University of South Florida - Tampa

Michigan

  • Oakland Medical Group - Detroit
  • Corewell Health - Grand Rapids
  • Revive Clinical Research - Sterling

California

  • University of California Irvine Medical Center - Orange
  • University of California San Francisco at Mission Bay - San Francisco

Georgia

  • Northside Hospital - Atlanta
  • Georgia Cancer Center at Augusta University - Augusta

Maryland

  • Maryland Oncology Hematology - Annapolis
  • University of Maryland Medical Center - Baltimore

Alaska

  • Alaska Women's Cancer Care - Anchorage

Illinois

  • Northwestern University - Evanston

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2021-07-28
Est. Completion 2025-10-22
Phase Phase 2
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

8 total trials

What the finished NCT04814108 record still lists

NCT04814108 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, roughly in line with the 89-participant average among 4 other Uterine Serous Carcinoma trials with a reported enrollment target.

The record links to 1 condition, with Uterine Serous Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Azenosertib is the first listed.

NCT04814108 names 20 study sites across 11 states, led by Arizona, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT04814108 about?

NCT04814108 is a clinical study titled "A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma". This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

What is the current status of trial NCT04814108?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2021-07-28. Estimated completion is 2025-10-22.

What conditions does trial NCT04814108 study?

This clinical trial studies the following conditions: Uterine Serous Carcinoma.

What interventions are being tested in trial NCT04814108?

The interventions under investigation include: Azenosertib (DRUG).

Who is sponsoring clinical trial NCT04814108?

This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04814108 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uterine Serous Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03184545 · 92 participants · Phase 3

    Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome

  • NCT04172532 · 92 participants · Phase 1

    Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  • NCT04508088 · 92 participants

    Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

  • NCT04840602 · 92 participants · Phase 2

    Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04814108, the US trial registry maintained by the National Library of Medicine. NCT04814108 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.